Advances in Liver Fibrosis: From Mechanisms to Therapeutics
A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Molecular and Translational Medicine".
Deadline for manuscript submissions: 28 February 2026
Special Issue Editor
Interests: liver fibrosis; hepatic stellate cells; liver macrophages; G protein-coupled receptors; lncRNA; transcription factors
Special Issue Information
Dear Colleagues,
Liver fibrosis remains a critical global health challenge, representing a common pathological outcome of chronic liver injury caused by viral hepatitis, alcohol abuse, metabolic dysfunction, and other insults. Despite its reversible nature at early stages, the lack of effective diagnostic tools and targeted therapies often leads to progression toward cirrhosis and hepatocellular carcinoma. Recent advances in understanding the cellular and molecular mechanisms of liver fibrosis—particularly the dynamic interplay between hepatocytes, hepatic stellate cells (HSCs), hepatic macrophages (HMs), liver sinusoidal endothelial cells (LSECs), immune cells, and the extracellular matrix—have opened new avenues for therapeutic intervention.
This Special Issue aims to present a series of review and research articles focusing on new diagnostic and therapeutic targets for liver fibrosis, as well as novel technologies. We welcome basic and translational research or reviews that contribute to our understanding of the progression of liver fibrosis and potential diagnostic as well as therapeutic approaches.
Dr. Kun Zhang
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- liver fibrosis
- therapeutic target
- biomarker
- hepatocyte
- macrophage
- LSEC
- HSC
- immune cells
- extracellular matrix
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
